Biotechnology

Brainstorm Cell

Brainstorm Cell released FY2025 9 Months Earnings on November 14 (EST), with actual revenue of USD 0 and EPS of USD -0.9796

Brainstorm Cell released FY2025 Q3 earnings on November 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1913 (forecast USD -0.37)

Brainstorm Cell Therapeutics Inc. Completes $155,000 Private Placement Financing

Brainstorm Cell released FY2025 Semi-Annual earnings on August 14 After-Market (EST), actual revenue USD 0, actual EPS USD -0.7702

Brainstorm Cell released FY2025 Q2 earnings on August 14 After-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.34 (forecast USD -0.37)

Brainstorm Cell to Release FY2025 Q2 Earnings on August 14 After-Market (EST), Forecast Revenue USD 0, EPS USD -0.37

BrainStorm Announces 3b Phase Clinical Trial Plan for ALS Treatment Drug NurOwn

Brainstorm Submits Prospectus for Up to 2.8 Million Shares of Common Stock Offering and Sale

Brainstorm Shareholders Approve Seven Directors and Increase Common Stock Pool by 2 Million Shares

BrainStorm Cell Therapeutics Announces New Survival Data for ALS Treatment NurOwn

BrainStorm and Minaris Partner to Enhance ALS Clinical Trial Production Capacity

BrainStorm Cell Therapeutics Inc. Receives FDA Approval to Initiate Phase 3b Clinical Trial of NurOwn® for ALS

Brainstorm Cell released FY2025 Q1 earnings on May 15 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4515 (forecast USD -0.97)

BrainStorm Announces Q1 2025 Financials and NurOwn Program Updates

Brainstorm Company Posts a 97 Cent Loss Per Share in Q1 2025

Brainstorm Cell to Release FY2025 Q1 Earnings on May 15 After-Market EST, Forecasted Revenue USD 0, EPS USD -0.97

BrainStorm to Hold Conference Call to Discuss Q1 Financial Performance

BrainStorm Cell Secures Basic Patent for Exosome Technology

BrainStorm to Present ALS Treatment Data at International Society for Cell Therapy Annual Meeting

BrainStorm Cell Therapeutics Inc. Submits IND Amendment for New Drug

EKSO Bionics

Antelope Enterprise

Aimei Health Tech

Profusa

Delixy

Urgently

Jyong Biotech

Cemtrex

CID Holdco

ON24

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap